{"created":"2023-07-27T06:38:39.498291+00:00","id":26800,"links":{},"metadata":{"_buckets":{"deposit":"481f7669-92c0-4318-acea-d0f36c1fb271"},"_deposit":{"created_by":3,"id":"26800","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"26800"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00026800","sets":["1761:1762:1763"]},"author_link":["491","20454","45274","21459","45276","45278","45279","45275","329","45277","97"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-12-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"328","bibliographicPageStart":"323","bibliographicVolumeNumber":"336","bibliographic_titles":[{"bibliographic_title":"Biomedical research"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Interferon-alpha (IFN-α) has been used in systemic treatment for metastatic renal cell carcinoma (mRCC). IFN-α has at least 14 subtypes, each of which has different biological activity. There have been reports that mRCC resistant to an IFN-α treatment responded to another IFN-α subtype. This study was performed to evaluate the effectiveness of alternation of different IFN-α subtypes for mRCC that did not respond to initial IFN-α treatment. In our department and associated institutions, alternating therapy of IFN-α was provided for 15 initial IFN-α refractory mRCC cases from June 2005 to September 2008. Among the 15 patients, the effects of alternating IFN-α therapy were as follows: complete response (CR), 0 cases; partial response (PR), 1 case; stable disease (SD), 3 cases; progressive disease (PD), 11 cases. The response rate (CR+PR) was 7% and disease control rate (CR+PR+SD) was 27%. No severe side effects were observed in any of these cases. The PR case is still in PR 21 months after alternating IFN-α therapy. Among the three SD cases, one has continued SD for 14 months and the other for 12 months. Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective.","subitem_description_type":"Abstract"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Biomedical Research Foundation"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2220/biomedres.33.323","subitem_relation_type_select":"DOI"}}]},"item_4_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://japanlinkcenter.org/DN/JST.JSTAGE/biomedres/33.323","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.jstage.jst.go.jp/article/biomedres/33/6/33_323/_article","subitem_relation_type_select":"URI"}}]},"item_4_rights_23":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright © 2012 Biomedical Research Press"}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA12050384","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1880-313X","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kadono, Yoshifumi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Miwa, Sotaro"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Shima, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Konaka, Hiroyuki"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Mizokami, Atsushi"}],"nameIdentifiers":[{},{},{},{}]},{"creatorNames":[{"creatorName":"Yotsuyanagi, Satoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hirata, Akio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Takase, Yasukazu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sugata, Toshiaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shimamura, Masayoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Namiki, Mikio"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-05"}],"displaytype":"detail","filename":"ME-PR-KADONO-Y-323.pdf","filesize":[{"value":"307.0 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-KADONO-Y-323.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/26800/files/ME-PR-KADONO-Y-323.pdf"},"version_id":"ce326f5a-4174-4a8d-88f9-0a64a3fdb627"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"The effectiveness of interferon-alpha subtypes alteration for metastasis from renal cell carcinoma","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"The effectiveness of interferon-alpha subtypes alteration for metastasis from renal cell carcinoma"}]},"item_type_id":"4","owner":"3","path":["1763"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-05"},"publish_date":"2017-10-05","publish_status":"0","recid":"26800","relation_version_is_last":true,"title":["The effectiveness of interferon-alpha subtypes alteration for metastasis from renal cell carcinoma"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-27T21:18:33.785133+00:00"}